Dublin, April 01, 2026 (GLOBE NEWSWIRE) — The “Advanced Renal Cell Carcinoma Treatment Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The report outlines opportunities for growth, with insights into emerging markets and segmentation to inform strategic endeavors in the advanced RCC treatment landscape.
The advanced renal cell carcinoma (RCC) treatment market has demonstrated significant growth, with projections indicating an increase from $8.73 billion in 2025 to $9.4 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.7%. This expansion results from limited treatment options for advanced RCC, reliance on conventional chemotherapy, rising prevalence of RCC, and the expansion of hospital oncology services and clinical research initiatives.
Looking ahead, the market is expected to reach $12.52 billion by 2030, with a CAGR of 7.4%. This growth is attributed to novel biologics, targeted inhibitors, investment in immunotherapy research, and the adoption of personalized medicine and minimally invasive procedures. Key trends include the adoption of targeted therapies, immune checkpoint inhibitors, combination therapy approaches, and the development of cancer vaccines.
The prevalence of genetic conditions is anticipated to drive the growth of the advanced RCC treatment market. With advancements in diagnostics, increased awareness, and environmental influences, genetic conditions are becoming more prevalent. Advanced RCC treatments target specific molecular pathways, offering personalized therapies for tumor development. For instance, Gene People estimated that 1 in 25 children in the UK are affected by genetic conditions, contributing to the market’s growth.
Major companies like Merck & Co. Inc. are developing innovative therapies such as hypoxia-inducible factor-2 alpha (HIF-2?) inhibitors. In December 2023, Merck received FDA approval for WELIREG (belzutifan), an oral HIF-2 inhibitor, providing a novel treatment for patients with limited options, enhancing outcomes and management of advanced RCC.
In December 2023, Exelixis Inc. partnered with Arcus Biosciences Inc. to develop cancer therapies, focusing on RCC and other tumors through the STELLAR-009 clinical trial. This collaboration aims to accelerate treatment innovation, benefitting the advanced RCC treatment arena.
Prominent players in the market include Pfizer Inc, Bristol-Myers Squibb, AstraZeneca, Novartis, Exelixis, and others, with North America being the largest region in 2025. The market is segmented across Asia-Pacific, Western Europe, North America, and other regions, with countries like the USA, UK, China, and Germany leading the charge.
Reasons to Purchase:
- Obtain a global perspective with coverage across 16 geographies.
- Evaluate macro factors impacting the market, including geopolitical conflicts, trade policies, tariffs, inflation, interest rate fluctuations, and regulatory changes.
- Develop regional and country strategies based on local data and analyses.
- Identify investment opportunities in growth segments.
- Leverage forecast data and market trends to outperform competitors.
- Gain insights into end-user behavior.
- Benchmark against competitors by market share, innovation, and brand strength.
- Assess market potential through total addressable market evaluation and market attractiveness scores.
- Support presentations with high-quality data and analyses.
- Receive regularly updated data and comprehensive Excel summaries for ease of analysis.
Report Scope
Markets Covered:
- By Treatment: Biologics; Radiation Therapy
- By Route of Administration: Parental; Oral; Other
- By End User: Hospitals; Cancer Research Institutes
Subsegments:
- By Biologics: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Targeted Small Molecule Inhibitors
- By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiation Therapy (SBRT)
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Delivery Format: Available in Word, PDF, Interactive Report, plus Excel Dashboard
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $9.4 Billion |
| Forecasted Market Value (USD) by 2030 | $12.52 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
The companies featured in this Advanced Renal Cell Carcinoma Treatment market report include:
- Pfizer Inc
- Merck & Co Inc
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Novartis International AG
- Exelixis Inc
- Ipsen SA
- Eisai Co Ltd
- Roche Holding AG
- Genentech Inc
- Bayer AG
- Johnson & Johnson
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc
- BeiGene Ltd
- HUTCHMED China Limited
- Regeneron Pharmaceuticals Inc
- Eli Lilly and Company
- Amgen Inc
For more information about this report visit https://www.researchandmarkets.com/r/4ngp0p
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Advanced Renal Cell Carcinoma Treatment Market
